Clinical trial
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory…
NCT00112372 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00112372 |
|---|---|
| Title | Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) |
| Official title | A Phase I/IIa, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of AP23573 When Administered Orally in Patients With Refractory or Advanced Malignancies |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Ridaforolimus |
| Enrollment | 147 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Jun 3, 2005 |
| Last update posted | Feb 12, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: